Drug Approval | January 17, 2025
FDA issues five observations to Jubilant Pharmova’s Salisbury facility in USA
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
The brand Magtein by Threotech has a sales value of approximately US $438 million
Morepen Laboratories approves hiving off of medical devices business
atulya keratin & wheat protein shampoo has force of natural ingredients like extract of wheat, fenugreek, reetha & almond oil
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Biocon Biologics remains committed to global standards of quality and compliance
Subscribe To Our Newsletter & Stay Updated
